Navigation Links
NeurogesX Initiates Dosing in Phase 1 Clinical Trial for NGX-1998 Capsaicin Liquid Formulation
Date:7/11/2008

SAN MATEO, Calif., July 11 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced the initiation of its Phase 1 clinical trial (study C203) of NGX-1998. The product candidate is a high-concentration, capsaicin-based liquid formulation designed to deliver a localized therapeutic dose directly to the pain site.

The randomized, single-blind Phase 1 trial is designed to evaluate potential control formulations for future NGX-1998 clinical trials. NeurogesX expects to complete the trial by the end of 2008.

Anthony DiTonno, President and CEO of NeurogesX, commented, "The initiation of this Phase 1 trial of NGX-1998 marks a significant step in our program to develop a second-generation liquid formulation of capsaicin to manage pain. We believe that our Phase 1 trial will provide us with important information that will help shape the design of further studies with the product candidate. We are pleased with the Company's progress with NGX-1998 advancing in the clinic and NGX-4010 under regulatory review in Europe and approaching NDA submission in the United States."

About NGX-1998

NGX-1998 is a topically applied, high-concentration liquid formulation of capsaicin designed to treat pain associated with neuropathic pain conditions. The objective of the NGX-1998 development program is to determine the ability of NGX-1998 to provide protracted pain relief from a single treatment. Similar to NGX-4010, the Company's late-stage dermal patch that also contains a high concentration of capsaicin, NGX-1998 is designed to deliver localized pain relief however, with a shorter treatment procedure time and potentially wit
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
2. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
3. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
4. NeurogesX Announces Preliminary Results from Second Phase 3 Clinical Trial in HIV-DSP
5. NeurogesX Announces Publication of NGX-4010 Phase 3 HIV-Neuropathy Study Results in Neurology
6. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
7. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
8. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
9. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
10. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
11. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/9/2009)..., BATESVILLE, Ind. and MCDONOUGH, Ga., Nov. 9 /PR...d Encompass Group today announced the formation of...istribution of a comprehensive range of surface re...arate from a bed frame and as replacements for sur...end of their useful life. Hill-Rom, a global lead...
(Date:11/9/2009)..., ,, PRINCETON, N.J., Nov. 9 /PRNewswire...nnounces management will present at the Sixth Annu...he conference will be held at the St Regis Hotel i...efer Price, Pharmasset,s President and Chief Execu...any on Wednesday, November 18, 2009 at 3:45 PM (ET...
(Date:11/9/2009)..., HOUSTON, Nov. 9 Patent attorne...tipkala, Ph.D., J. D., will showcase Stipkala LLC ...3, 2009, which will be held at the Institute of Mo...cience Conference provides a platform for cutting-...ties to investors, and will feature keynote addres...
Breaking Medicine Technology:Hill-Rom and Encompass Group Form Joint Venture 2Hill-Rom and Encompass Group Form Joint Venture 3Hill-Rom and Encompass Group Form Joint Venture 4Hill-Rom and Encompass Group Form Joint Venture 5Pharmasset to Present at Lazard Capital Markets Healthcare Conference 2Pharmasset to Present at Lazard Capital Markets Healthcare Conference 3Feel Fun Fit 26 Fabulous 21 At the 2009 Womens Health Conference 52117 1Feel Fun Fit 26 Fabulous 21 At the 2009 Womens Health Conference 52117 2Feel Fun Fit 26 Fabulous 21 At the 2009 Womens Health Conference 52117 3Our brain looks at eyes first to identify a face 9280 1Our brain looks at eyes first to identify a face 9280 2Our brain looks at eyes first to identify a face 9280 3Scholarships Available for PA Breast Cancer Coalition Annual Conference 52115 1Scholarships Available for PA Breast Cancer Coalition Annual Conference 52115 2
...,Contributing Editor , ,Positive patient ide...editing bodies for the past few years. Until rece...are were beyond the reach of the average hospital ...ith devices that can be integrated into a facility...ter for small facilities, while others are best fo...
...vard Medical School ,Contributing Editor , ,...per year, breast cancer undoubtedly qualifies as o...ntly, efforts to develop early detection methods a...ress. This is particularly true at the molecular ...e translated into new diagnostic tests and targete...
Other Medicine Technology:Managing Preanalytical Processes for Patient Safety 2Managing Preanalytical Processes for Patient Safety 3Managing Preanalytical Processes for Patient Safety 4Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy 2Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy 3
(Date:11/10/2009)...e to achieve exceptionally smooth surface finishin...such as ceramics, carbide and hardened tool steel ...-Hone® honing tool from Brush Research Techn...EB) November 10, 2009 -- Using exclusive, self-sha...lexible filaments, the Diamond Flex-Hone is a pate...
(Date:11/10/2009)...ecognized child and family therapy pioneer B. Brya...f resources on healthy newborn attachment and emot...kers of the world-famous swadder Miracle Blanket....ing™, will offer a valuable online resource ...d independent retail shops alongside Miracle Blank...
(Date:11/9/2009)...he worldwide leader in sports surfacing, enhances ...more complete and innovative range of sports floor...experts and the launch of www.tarkettsportsindoor... 9, 2009 -- Tarkett Sports, redesigned line of Nor...es hardwood and synthetic basketball, volleyball a...
(Date:11/9/2009)...ted During Broadcast ,, WASHINGTON, Nov. 9 /PR... announced that LCA staff, advocates and friends w...xchange(TM) (NYSE) tomorrow afternoon at 4 pm ET. ...nh/20081016/LCALOGO ) ,, Five and a half year ...Heimler will mark the end of the day,s trading by ...
(Date:11/9/2009)...e/ -- Sutter Health, a family of doctors, not-for-...viders, is donating $255,000 to food banks across ... will share the quarter-million-dollar donation to...ands of families across the north state. ,, S... and supporting charitable programs and services. ...
Breaking Medicine News(10 mins):Health News:Diamond Honing Tool Technology: The New Standard in Surface Finishing of Hard Materials 2Health News:Attachment & Emotional Development Expert Teams Up with Miracle Industries, LLC. to Launch Valuable Parenting Resource 2Health News:Attachment & Emotional Development Expert Teams Up with Miracle Industries, LLC. to Launch Valuable Parenting Resource 3Health News:Attachment & Emotional Development Expert Teams Up with Miracle Industries, LLC. to Launch Valuable Parenting Resource 4Health News:Tarkett Sports Launches Revamped Indoor Sports Flooring Division and New Indoor Website 2Health News:Lung Cancer Alliance Staff and Advocates to Ring Closing Bell of New York Stock Exchange(TM) 2Health News:Sutter Health Donates $255,000 to Help the Hungry This Holiday Season 2
...ohn Paul in Scotland in 1747, is linked to the Uni...nd victory. He first went to sea at age 13, became...l officer during the American Revolution. Despite ...ones is the subject of this year,s Historical Clin...
... Brookdale Senior Living Inc. (NYSE: BKD ) annou...ter 2009 financial results after the market closes...scheduled a conference call to discuss the results...m outside of the U.S.) ten minutes prior to the sc...
...t label warnings for Procrit, Aranesp, experts say...-- Two new studies provide more evidence that drug...r patients to fight anemia-linked fatigue, may boo...sociated in prior studies with increased risk of h...
...Solta Medical, Inc. (Nasdaq: SLTM ), a global le...nced that it has received regulatory clearance to ... are excited about the opportunity to market the p...resident and CEO of Solta Medical. "We have also a...
...hing as Key Precaution , , NEW YORK, April 30 As...und the world are taking proactive steps to protec...g up on over-the-counter flu medication can help y...80 percent of infections spread through hand conta...
...mucor, Inc. (Nasdaq: BLUD ), a global leader in ...the blood transfusion industry, today announced th...ca and Merrill Lynch 2009 Health Care Conference i...p.m. Eastern time. Access to the presentation will...
Other Medicine News:Health News:What killed Naval hero John Paul Jones? 2Health News:What killed Naval hero John Paul Jones? 3Health News:What killed Naval hero John Paul Jones? 4Health News:Brookdale Announces First Quarter 2009 Release and Earnings Call 2Health News:Anemia Drugs May Raise Death Risk in Cancer Patients 2Health News:Anemia Drugs May Raise Death Risk in Cancer Patients 3Health News:Anemia Drugs May Raise Death Risk in Cancer Patients 4Health News:Solta Medical Receives Regulatory Approval to Market Thermage Systems in China 2Health News:Photos: How You Can Help Protect Yourself & Your Family From Swine Flu (H1N1) 2Health News:Photos: How You Can Help Protect Yourself & Your Family From Swine Flu (H1N1) 3
Thyroglobulin Autoantibody - ELISA
Coat-a-Count Estradiol RIA
... the quantitative determination of Estradiol (E2) ...(E2) is a C18 steroid hormone with a phenolic A ri...f 272.4. It is the most potent natural Estrogen, ...ller amounts by the adrenal cortex, and the male t...
AxSYM Troponin-I ADV
Medicine Products: